These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 8436740)

  • 1. Lack of impact of early catheterization and fibrin specificity on bleeding complications after thrombolytic therapy. The TAMI Study Group.
    Wall TC; Califf RM; Ellis SG; Sigmon K; Kereiakes D; George BS; Samaha J; Sane D; Stump DC; Stack RS
    J Am Coll Cardiol; 1993 Mar; 21(3):597-603. PubMed ID: 8436740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of combination thrombolytic therapy and timing of cardiac catheterization in acute myocardial infarction. Results of thrombolysis and angioplasty in myocardial infarction--phase 5 randomized trial. TAMI Study Group.
    Califf RM; Topol EJ; Stack RS; Ellis SG; George BS; Kereiakes DJ; Samaha JK; Worley SJ; Anderson JL; Harrelson-Woodlief L
    Circulation; 1991 May; 83(5):1543-56. PubMed ID: 1902405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial.
    Bovill EG; Terrin ML; Stump DC; Berke AD; Frederick M; Collen D; Feit F; Gore JM; Hillis LD; Lambrew CT
    Ann Intern Med; 1991 Aug; 115(4):256-65. PubMed ID: 1906692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of benefit of combination thrombolytic therapy for acute myocardial infarction: a quantitative angiographic and hematologic study.
    Popma JJ; Califf RM; Ellis SG; George BS; Kereiakes DJ; Samaha JK; Worley SJ; Anderson JL; Stump D; Woodlief L
    J Am Coll Cardiol; 1992 Nov; 20(6):1305-12. PubMed ID: 1430679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accelerated plasminogen activator dose regimens for coronary thrombolysis. The TAMI-7 Study Group.
    Wall TC; Califf RM; George BS; Ellis SG; Samaha JK; Kereiakes DJ; Worley SJ; Sigmon K; Topol EJ
    J Am Coll Cardiol; 1992 Mar; 19(3):482-9. PubMed ID: 1537998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New developments in thrombolytic therapy.
    Collen D; Gold HK
    Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombolytic therapy for women with myocardial infarction: is there a gender gap? Thrombolysis and Angioplasty in Myocardial Infarction Study Group.
    Lincoff AM; Califf RM; Ellis SG; Sigmon KN; Lee KL; Leimberger JD; Topol EJ
    J Am Coll Cardiol; 1993 Dec; 22(7):1780-7. PubMed ID: 8245328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of thrombolytic regimen, early catheterization, and predischarge angiographic variables on six-week left ventricular function. The TAMI Investigators. Thrombolysis and Angioplasty in Acute Myocardial Infarction.
    Ward SR; Sutton JM; Pieper KS; Schwaiger M; Califf RM; Topol EJ
    Am J Cardiol; 1997 Mar; 79(5):539-44. PubMed ID: 9068505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemorrhagic complications associated with the use of intravenous tissue plasminogen activator in treatment of acute myocardial infarction.
    Califf RM; Topol EJ; George BS; Boswick JM; Abbottsmith C; Sigmon KN; Candela R; Masek R; Kereiakes D; O'Neill WW
    Am J Med; 1988 Sep; 85(3):353-9. PubMed ID: 3137818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group.
    Granger CB; Califf RM; Young S; Candela R; Samaha J; Worley S; Kereiakes DJ; Topol EJ
    J Am Coll Cardiol; 1993 Mar; 21(4):920-5. PubMed ID: 8450161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serial changes in coagulant activities after thrombolytic therapy for acute myocardial infarction.
    Goto S; Kawai Y; Abe S; Takahashi E; Handa S; Ogawa S; Watanabe K; Hori S; Ikeda Y
    Angiology; 1994 Apr; 45(4):273-81. PubMed ID: 8161005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombolysis with recombinant unglycosylated single-chain urokinase-type plasminogen activator (saruplase) in acute myocardial infarction: influence of heparin on early patency rate (LIMITS study). Liquemin in Myocardial Infarction During Thrombolysis With Saruplase.
    Tebbe U; Windeler J; Boesl I; Hoffmann H; Wojcik J; Ashmawy M; Rüdiger Schwarz E; von Loewis P; Rosemeyer P; Hopkins G
    J Am Coll Cardiol; 1995 Aug; 26(2):365-73. PubMed ID: 7608436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Procoagulant effects of thrombolytic therapy in acute myocardial infarction.
    Wang Y; Liu Q; Zhu J; Yuan Z; Ma X
    Chin Med Sci J; 2002 Mar; 17(1):36-9. PubMed ID: 12894883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased serum levels of fibrinogen degradation products due to treatment with recombinant tissue-type plasminogen activator for acute myocardial infarction are related to bleeding complications, but not to coronary patency. European Co-operative Study Groups for rt-PA.
    Arnold AE; Brower RW; Collen D; van Es GA; Lubsen J; Serruys PW; Simoons ML; Verstraete M
    J Am Coll Cardiol; 1989 Sep; 14(3):581-8. PubMed ID: 2504798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group.
    Grines CL; Browne KF; Marco J; Rothbaum D; Stone GW; O'Keefe J; Overlie P; Donohue B; Chelliah N; Timmis GC
    N Engl J Med; 1993 Mar; 328(10):673-9. PubMed ID: 8433725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged activation of fibrinolytic system induced by fibrin nonselective thrombolytic agent can contribute to preventing early reocclusion after coronary thrombolytic therapy.
    Goto S; Kawai Y; Handa S; Takahashi E; Ogawa S; Watanabe K; Hori S; Ikeda Y
    Cardiology; 1993; 82(4):274-9. PubMed ID: 8402754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bleeding time and other laboratory tests to monitor the safety and efficacy of thrombolytic therapy.
    Hirsch DR; Goldhaber SZ
    Chest; 1990 Apr; 97(4 Suppl):124S-131S. PubMed ID: 2108850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
    Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
    J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical importance of thrombocytopenia occurring in the hospital phase after administration of thrombolytic therapy for acute myocardial infarction. The Thrombolysis and Angioplasty in Myocardial Infarction Study Group.
    Harrington RA; Sane DC; Califf RM; Sigmon KN; Abbottsmith CW; Candela RJ; Lee KL; Topol EJ
    J Am Coll Cardiol; 1994 Mar; 23(4):891-8. PubMed ID: 8106694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential combination thrombolytic therapy for acute myocardial infarction: results of the Pro-Urokinase and t-PA Enhancement of Thrombolysis (PATENT) Trial.
    Zarich SW; Kowalchuk GJ; Weaver WD; Loscalzo J; Sassower M; Manzo K; Byrnes C; Muller JE; Gurewich V
    J Am Coll Cardiol; 1995 Aug; 26(2):374-9. PubMed ID: 7608437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.